As of 2025-07-20, the Relative Valuation of Innate Pharma SA (IPH.PA) is (2.17) EUR. This relative valuation is based on P/E multiples. With the latest stock price at 1.72 EUR, the upside of Innate Pharma SA based on Relative Valuation is -226.5%.
The range of the Relative Valuation is (1.72) - (3.36) EUR.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 2.6x - 6.3x | 3.3x |
| Forward P/E multiples | 3.2x - 6.9x | 4.8x |
| Fair Price | (1.72) - (3.36) | (2.17) |
| Upside | -200.0% - -295.6% | -226.5% |
| Date | P/E |
| 2025-07-18 | -3.20 |
| 2025-07-17 | -2.94 |
| 2025-07-16 | -2.91 |
| 2025-07-15 | -2.80 |
| 2025-07-14 | -2.75 |
| 2025-07-11 | -2.80 |
| 2025-07-10 | -2.82 |
| 2025-07-09 | -2.85 |
| 2025-07-08 | -2.81 |
| 2025-07-07 | -2.85 |
| 2025-07-04 | -2.84 |
| 2025-07-03 | -2.84 |
| 2025-07-02 | -2.83 |
| 2025-07-01 | -2.85 |
| 2025-06-30 | -2.84 |
| 2025-06-27 | -2.91 |
| 2025-06-26 | -2.88 |
| 2025-06-25 | -2.82 |
| 2025-06-24 | -2.80 |
| 2025-06-23 | -2.85 |
| 2025-06-20 | -2.96 |
| 2025-06-19 | -3.07 |
| 2025-06-18 | -3.10 |
| 2025-06-17 | -3.07 |
| 2025-06-16 | -3.09 |
| 2025-06-13 | -3.15 |
| 2025-06-12 | -3.19 |
| 2025-06-11 | -3.26 |
| 2025-06-10 | -3.33 |
| 2025-06-09 | -3.52 |
| 2025-06-06 | -3.57 |
| 2025-06-05 | -3.57 |
| 2025-06-04 | -3.60 |
| 2025-06-03 | -3.62 |
| 2025-06-02 | -3.61 |
| 2025-05-30 | -3.68 |
| 2025-05-29 | -3.69 |
| 2025-05-28 | -3.65 |
| 2025-05-27 | -3.58 |
| 2025-05-26 | -3.66 |
| 2025-05-23 | -3.66 |
| 2025-05-22 | -3.67 |
| 2025-05-21 | -3.64 |
| 2025-05-20 | -3.65 |
| 2025-05-19 | -3.61 |
| 2025-05-16 | -3.57 |
| 2025-05-15 | -3.58 |
| 2025-05-14 | -3.64 |
| 2025-05-13 | -3.71 |
| 2025-05-12 | -3.75 |